Eli Lilly Acquires Verve for $1.3B to Boost In Vivo Gene Editing for Heart Disease

Published on Spencer Knight via LinkedIn

Eli Lilly has announced plans to acquire Verve Therapeutics in a deal worth up to $1.3 billion. That includes $1 billion upfront and an additional $300 million tied to clinical milestones. Verve’s lead program uses in vivo base editing to lower LDL cholesterol by targeting key genetic pathways involved in cardiovascular disease.

The acquisition expands Lilly’s cardiovascular pipeline and builds on its existing collaboration with Verve. Spencer Knight sees this as a strategic move that combines early-stage innovation with Lilly’s strong commercial momentum from blockbuster metabolic drugs like Mounjaro.

Read the full post on LinkedIn:

👉 Spencer Knight: Eli Lilly Makes $1.3B Gene-Editing Acquisition

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.